High levels of lipoprotein(a) often go undetected and can afflict seemingly healthy people. A clinical trial will show whether lowering levels can reduce risk of heart disease.

Millions of Americans are born genetically predisposed to extremely high levels of a type of cholesterol that cause deadly heart attacks and strokes by middle age, yet they are almost always unaware ...

All sex, race, and risk category groups appeared to be affected by the heart disease risk posed by elevated lipoprotein(a), or Lp(a), according to pooled analysis of primary prevention studies.

Following these positive 36-week results, Silence Therapeutics plans to announce 48-week results of the ongoing ALPACAR-360 study in Q2 of 2024. Silence Therapeutics has released promising findings ...

Jeffrey Frist was getting desperate. Diagnosed with familial hypercholesterolemia (FH) in 2012 after his first heart attack the year before, he had experienced a cardiovascular event every 11 months ...

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over ...

Moderate alcohol consumers, i.e., those who consume 1–2 alcoholic drinks daily, are 20% less likely to contract coronary heart disease (CHD) in their middle years than non-drinkers. Interestingly, ...

Elevated lipoprotein(a) levels can slowly block the arteries, increasing the likelihood of cardiovascular disease. Since no treatment is currently available for this condition, it is essential to ...

However, accumulating evidence over the past two decades demonstrates that a biomarker called C-reactive protein —which ...